BeOne Medicines (ONC) President Lai Wang Sells $296K of Stock
Lai Wang, President of Global R&D at BeOne Medicines, sold 1,068 shares valued at $295,558.
Reviewed by automated data checks against the source filing. How we make and check alerts
Lai Wang, President, Global Head of R&D at BeOne Medicines AG ($ONC), sold 1,068 shares at an average price of $276.74, worth about $295,558.32, on June 23, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $ONC is up 3.2% after 1 week, up 18.3% after 1 month and up 33.6% to date (from the $276.13 close on Jun 23, 2026).
ONC
BeOne Medicines AG
Key Points
- Lai Wang, President of Global R&D at BeOne Medicines, sold 1,068 shares at $276.74 each on June 23.
- Shares of BeOne Medicines (ONC) traded at $277.12 on Friday, with a market cap of $28.2 billion and a P/E ratio of 61.35.
- RBC Capital and others maintain 'buy' ratings with targets up to $436, while Jefferies downgraded to 'hold' with a $290 target.
Get $ONC trade alerts by text
We text you when insiders, Congress or big funds trade $ONC. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated BeOne Medicines AG alert may contain errors. Disclosures
Lai Wang, the President and Global Head of R&D at BeOne Medicines AG, sold 1,068 shares of the company on June 23. The shares were sold at an average price of $276.74, resulting in a total transaction value of $295,558. This sale was not part of a pre-planned trading program.
Insider Buying and Selling at BeOne Medicines AG
In addition to Lai Wang's transaction, other insiders at BeOne Medicines have been active. On the same day, CEO John Oyler sold 3,410 shares, and President and COO Xiaobin Wu sold 1,292 shares. These transactions were also not pre-planned.
BeOne Medicines AG Stock Down 26.4%
Shares of NasdaqGS:ONC traded near $277.12 on Friday. BeOne Medicines AG has a market capitalization of approximately $28.2 billion. The company has a P/E ratio of 61.35 and a forward P/E of 27.98, with a beta of 0.493. Over the past 52 weeks, the stock has ranged from a low of $239.25 to a high of $385.22. The 50-day moving average is $295.53, while the 200-day moving average stands at $318.35.
Analysts Set New Price Targets
Several analysts have recently weighed in on BeOne Medicines. RBC Capital maintained its 'buy' rating with a price target of $436 on June 2. Other firms like Leerink Partners and Guggenheim also upheld 'buy' ratings with targets of $367 and $420, respectively. Jefferies, however, downgraded the stock to 'hold' with a $290 target in March.
About BeOne Medicines
BeOne Medicines AG, headquartered in Basel, Switzerland, is a biotechnology company focused on developing treatments for cancer. It operates in the United States, China, and Europe. The company offers several commercial products, including BRUKINSA and TEVIMBRA, and is engaged in multiple clinical trials. BeOne Medicines was formerly known as BeiGene, Ltd. and changed its name in May 2025. It employs around 12,000 people and is led by CEO John V. Oyler.
Bottom Line
Lai Wang's sale of shares in BeOne Medicines AG highlights ongoing insider activity at the company. Investors keep a close eye on such transactions to gauge insider sentiment. While insider trading provides some insight, it's important to remember that these filings are backward-looking and may not reflect current positions or future intentions.
Related Filing Alerts
Source: Lai Wang's Form 4 filing on $ONC (Jun 23, 2026). Find the original filing: ONC Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts